Compare · ARGX vs NMRA
ARGX vs NMRA
Side-by-side comparison of argenx SE (ARGX) and Neumora Therapeutics Inc. (NMRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and NMRA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.52B, about 173.9x NMRA ($302.0M).
- Over the past year, ARGX is up 53.0% and NMRA is down 15.4% - ARGX leads by 68.4 points.
- ARGX has hit the wire 1 time in the past 4 weeks while NMRA has been quiet.
- ARGX has more recent analyst coverage (25 ratings vs 23 for NMRA).
- Company
- argenx SE
- Neumora Therapeutics Inc.
- Price
- $866.62+2.31%
- $1.65+1.23%
- Market cap
- $52.52B
- $302.0M
- 1M return
- -1.29%
- +9.30%
- 1Y return
- +52.99%
- -15.42%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2023
- News (4w)
- 1
- 0
- Recent ratings
- 25
- 23
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Latest NMRA
- H.C. Wainwright reiterated coverage on Neumora Therapeutics with a new price target
- Needham reiterated coverage on Neumora Therapeutics with a new price target
- Neumora Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Costs Associated with Exit or Disposal Activities
- Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
- SEC Form 4 filed by Director Burow Kristina
- SEC Form 4 filed by Director Fust Matthew K
- SEC Form 4 filed by Director Piacquad David
- SEC Form 4 filed by Director Halawa Alaa
- SEC Form 4 filed by Director Ho Maykin
- SEC Form 8-K filed by Neumora Therapeutics Inc.